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ActivatableThe advent of nanoparticle DDSs (drug delivery systems, nano-DDSs) is opening newpathways to understanding
physiology and pathophysiology at the nanometer scale. A nano-DDS can be used to deliver higher local concen-
trations of drugs to a target region andmagnify therapeutic effects. However, interstitial cells or ﬁbrosis in intrac-
table tumors, as occurs in pancreatic or scirrhous stomach cancer, tend to impede nanoparticle delivery. Thus, it is
critical to optimize the type and size of nanoparticles to reach the target. High-resolution 3D imaging provides a
means of “seeing” the nanoparticle distribution and therapeutic effects.We introduce the concept of “nano-path-
ophysiological imaging” as a strategy for theranostics. The strategy consists of selecting an appropriate nano-DDS
and rapidly evaluating drug effects in vivo to guide the next roundof therapy. In this articlewe classify nano-DDSs
by component carrier materials and present an overview of the signiﬁcance of nano-pathophysiological MRI.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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As noted in previous chapters, the advent of nanoparticle drug deliv-
ery systems (DDSs) is openingnewpathways to understanding physiol-
ogy andpathophysiology at the nanometer scale. One of these pathways
lies in themerger of DDSs with high-resolution, 3Dmagnetic resonance
imaging (MRI). In this chapter, we review the pioneering concepts and
research that have emerged from thismerger, and predict the changes it
may bring to medicine.
MRI is based on the resonance between radio waves of a speciﬁc fre-
quency and themagneticmoments of protons inwatermolecules in liv-
ing tissue. This resonance is observed in the presence of a large, static
magnetic ﬁeld. MRI is widely used in clinical diagnosis. Unlike X-ray
computed tomography (CT), it involves no exposure to ionizing radia-
tion and provides high contrast in soft tissue. Moreover, unlike nuclear
imagingmethods such as positron emission tomography (PET) or single
photon emission computed tomography (SPECT),MRI enablesmorpho-
logical imaging in 3D with high spatial resolution and can be used to
measure blood ﬂow, water diffusion, andmany other functional param-
eters, co-registered with high-resolution anatomical images. In recent
years the development of high-sensitivity receiving coils, particularly
cryogenically cooled coils, and the use of higher magnetic ﬁeld
strengths, have enabled practical micro-imaging in spatial resolutions
of 20–50 μm for small animals, bringing the resolution of MRI into the
same range as that of low-magniﬁcation light microscopy in brain [1]
or in tumors (Fig. 1).
A nanoparticle-based DDS (Nano-DDS) is deﬁned as an agent to de-
liver drugs to organs, tissues or cells using nanoparticles. However,most
nanoparticles accumulate in the liver following intravenous injection
and do not accumulate in the target tissue in sufﬁcient concentrationsfor diagnostic or therapeutic purposes. To avoid accumulation in the
liver and thereby prolong their residence time in circulation, nanoparti-
cles are often covalently attached to polyethylene glycol (PEG) polymer
chains on the surface through “PEGylation”. PEGylation increases the
opportunity for nanoparticles to accumulate at the target. In “passive
targeting” of tumors, for example, PEGylated nanoparticles of approxi-
mately 30–150 nmcan accumulate in the tumor through enhanced per-
meability and retention (EPR) due to increased tumor vasculature
permeability, prolonging retention of the nanoparticles in the tumor
[2]. In “active targeting”, nanoparticles with antibody, peptide, or pro-
tein coatings can bind speciﬁcally to the surfaces of tumor cells or to
neovascular endothelial cells, despite having a lower blood half-life.
With targeted drugs, a nano-DDS can be used to deliver higher local
concentrations in the target region thanwith small-molecule drugs, and
nano-DDSs hold promise for delivery that magniﬁes therapeutic effects
and reduces side effects of the delivered drug. However, certain chal-
lenges remain, as shown by the limited performance of the ﬁrst clinical-
ly approved PEGylated liposome (Doxil™) [3]. In immunodeﬁcient
animal models the liposome exhibited marked antitumor effects. How-
ever, in clinical applications the liposomes exhibited efﬁcacy against
only a limited number of tumors, such as Kaposi's sarcoma. This can
be attributed to the complexity of tumormorphology during the succes-
sive stages of inﬂammation, ﬁbrillization, hemorrhage, and repair that
occur repeatedly in the process of tumor formation and growth in
humans. In intractable tumors, such as those of pancreatic or scirrhous
stomach cancer, interstitial cells tend to proliferate and impede nano-
particle delivery. Nanoparticle delivery can be improved in these cases
by the concurrent use of TGF-β blockers [4]. In pancreatic cancer
models, only polymeric nano-micelles with a diameter of 30 nm, but
not with a diameter of 100 nm, can be delivered [5]. This illustrates
Fig. 1. MR micro-angiography of subcutaneously transplanted mouse tumor model after liposomal contrast agent administration (Gadolisome™). MRI was acquired using 7 Tesla
horizontal MRI (Bruker Biospin, Germany) with cooled radiofrequency coil for transmission and reception (cryoprobe™, Bruker Biospin). 3D angiography was obtained immediately
after Gd-dendron-PEGylated-nano-liposome (100 nm, DS Pharma Biomedical, Japan) using incoherent gradient-echo sequence at 50 μm isotropic spatial resolution (TR/TE = 15/2.5,
FA = 20°, FOV = 12.8 × 12.8 × 12.8 mm3, NEX = 3, scan time = 35 min). (Left) Colon-26 cells transplanted model. (Right) Human Burkitt's lymphoma cells (Raji) in a transplant
model. Note that different microstructures of vessels (both small arteries and veins) were clearly visualized inside tumor in vivo. High ﬁeldMRI with nano-DDS contrast agents will enable
in vivo imaging of the tumor microvasculature and intratumoral distribution of the particles.
Fig. 2. Is it possible to characterize tumor drug delivery by observing characteristic differ-
ences in the kinetics of various nanoscale probes? Tumors have great heterogeneity at the
cellular and tissue level, such as in density of stromal cells and structure of blood vessels.
This heterogeneity varies with the staging, treatment process and/or the immune re-
sponses of the individuals. Thus, nano-DDSs should be chosen in accordancewith changes
of the tumor microenvironment. In vivo 3D micro-imaging provides a means of “seeing”
the nanoparticle distribution and therapeutic effects.
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sistance at the cellular level or by small-molecule drug and antibody
targeting alone. The delivery of small molecules and 30 nm and
100 nm nanoparticles depends on the tumor microenvironment and
microcirculation [5,6]. It may be possible tomodulate tumor drug deliv-
ery by understanding the characteristic differences in the kinetics of the
various nanoscale probes.
The tissue concentration of a nano-DDS in a tumor depends on the
tumormicrostructure. Because of this, a nano-DDS cannot always be de-
livered into an intractable tumor in sufﬁcient concentrations. Tumors
vary greatly in cellularity and tissue microstructure. This variation is
also affected by staging, treatment and the immune response of each in-
dividual. Thus, nano-DDSs should be chosen to match the tumor micro-
environment. To achieve a nano-DDS that maximizes therapeutic gains
and minimizes side effects, it will be necessary to know which size or
types of nanoparticles can reach to the targeted tumor, which drug con-
centrations can be achieved inside the targeted tissue, and how therapy
can be delivered over a sufﬁcient time-frame (Fig. 2). For this purpose,
3Dmicro-imagingwill be critical to “see” the distribution and therapeu-
tic effects of a nano-DDS. We deﬁne the concept of “nano-pathophysio-
logical imaging” as a strategy for diagnostics and therapeutics 1) by
assessment of pathology with nanoprobes, 2) selecting the appropriate
nano-DDS, and 3) immediately assessing drug effects to guide the next
round of therapy.
Carriers for nano-DDSs can contain multiple components, such as
therapeutic drugs, MRI contrast agents, ﬂuorescent or luminescent
dyes, or radioisotopes, without serious changes to the nanoparticle ki-
netics/dynamics. The development of such multifunctional nano-DDSs
and imaging has thus become a subject of active research. For example,
there are bi-modal or multi-modal particles, imaging agents combined
with therapeutic drugs, and particles that enable triggered drug release
or triggered therapy. Variousmaterials have also been reported as nano-
DDS carriers, including micelles [7,8], liposomes [9–11], emulsions [12,
13], dendrimers [14,15], quantum dots (QDs) [16,17] and carbon mate-
rials such as fullerenes [18,19], with each material providing a different
set of characteristics as a nano-DDS carrier. We believe that a strong
foundation of useful materials has been established to realize nano-
pathophysiological imaging in combination with MR microimaging. In
this article, we classify nano-DDSs by the component carrier materials,
(e.g. polymer-, metal particle-, QD-, vesicle-, polymeric micelles-, and
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ing nano-DDSs with MRI. In addition, we focus on responsive
(activatable) and theranostic (both therapeutic and diagnostic) contrast
agents using the various carrier materials. This review is focused pri-
marily on MRI because it allows 3D mapping of the tissue microstruc-
ture and nano-DDS distribution after delivery.
2. MRI contrast agents
2.1. Overview of MRI contrast agents
Paramagnetic metal chelates, such as Gd-DTPA or Gd-DOTA, shorten
tissue longitudinal relaxation times (T1) and are often used as
‘positive’MRI contrast agents in preclinical and clinical studies. Follow-
ing intravenous administration, Gd3+-chelates, (molecular weight:
560–750 kDa), leak from capillaries and permeate the interstitial
space. The agents are then eliminated by the kidneys, exhibiting a 1–
1.5 h half-life in the blood. Intravenously injectedGd3+-chelates distrib-
ute in the parenchyma throughout entire body (apart from the brain),
and do not speciﬁcally accumulate in tumors. The dynamic enhance-
ment of the MRI signal by Gd3+-chelates can be used to measure tissue
perfusion and assist in tumor diagnosis. In the brain, on the other hand,
the Gd3+-chelate cannot leak from intact capillaries because the blood–
brain-barrier prevents leakage. Here, contrast agent accumulation
can thus serve as a marker for blood–brain-barrier disruption in dis-
eases such as brain tumors. These characteristics of small-molecule
Gd3+-chelates have long contributed to diagnosis and still play a
major role in the clinic today.
Nanoparticles have also been investigated asMRI contrast agents for
many years. For example, carboxydextran-coated superparamagnetic
iron oxide (SPIO) nanoparticles shorten tissue transverse relaxation
times (T2 and T2*), and have been used clinically as negative, (image
darkening), contrast agents for hepatic tumor diagnosis. Intravenously
injected SPIOs are readily taken up by Kupffer cells in the sinusoids of
the normal kidney, but not in tumor cells. Even though SPIO agents do
not target the tumor itself, SPIO accumulation forms image contrast
that allows detection of the tumor cells. SPIO nanoparticles have largely
been supplanted by gadoxetate disodium in diagnosis, but they are ex-
tensively used in basic research and preclinical studies, enabling new
avenues for exploration and development. For example, SPIOs have
been investigated for labeling [20] and tracking transplanted cells, ob-
serving the kinetics of intravenous injection [21], diagnosing lymph
node pathologies [22], and targeting tumors [23].
2.2. Hyperpolarized MRI contrast agents
One principle challenge of MRI contrast agents is that the change in
the MRI signal is usually detected indirectly through the effect of the
agent on thewater protonmagnetization.Hyperpolarization techniques
are used to create a netmagnetization through increasing the number of
proton spins in a single spin state (e.g. up vs. down). This enables amuch
higher net magnetization than is normally accomplished through the
Zeeman splitting in an ambient magnetic ﬁeld. While a primary limita-
tion of current hyperpolarized agents has been the T1 lifetime (after
which the magnetization decays), hyperpolarized contrast agents have
nonetheless begun to be useful in dynamic and targeted preclinical
studies.
The development of hyperpolarized agents has emerged in recent
years for highly sensitive detection of injected MRI contrast agents
[24]. The wide range of nuclei capable of hyperpolarization enhances
the variety of agents that are possible. For example, carbon-based
hyperpolarized agents can be useful as highly sensitive targeted agents
[25,26]. Yttrium-based agents have also been demonstrated with a long
T1-lifetime, raising the possibility of using these agents for awider range
of applications and functionality [27]. Recently, hyperpolarized siliconnanoparticles have been proposed for highly sensitive detection with
a long T1 [28–30].
3. Polymer-based contrast agents
3.1. Overview
Polymers are used in products like detergents, cosmetics, food, phar-
maceuticals and paints. Natural polymers, such as proteins, polysaccha-
rides, and nucleic acids that occur in the body have some potential
advantages in safety over synthetic polymers for biomedical use. In addi-
tion, many natural polymers perform biological functions that are useful
for imaging. In comparison, synthetic polymers formed frompolymeriza-
tion reactions can be readily created to perform a speciﬁc novel function.
Although themolecularweight distribution of synthetic polymers is gen-
erally broad, several synthesis methods have been developed to make
themmonodispersed [31].
Because water-soluble polymers have reactive groups such as hy-
droxyl, carboxyl or amine groups, it is easy tomodify their physicochem-
ical and biological properties.Water-soluble polymers serve as platforms
for contrast agents by incorporating multiple MRI probes and targeting
ligands in a single polymer. There are several derivatization techniques
to enable water-soluble polymers to spontaneously form nanoparticles,
such as polymer micelles, polymersomes, polyelectrolytes, and nano-
composites of metals and ceramics [32–34], as described in other parts
of this review. Polymer-based MRI contrast agents are prepared by con-
jugating Gd3+, Mn2+, PARACEST agents, or 19F MR agents to the water-
soluble polymer (Fig. 3A). Various reactive chelate residues are commer-
cially available, including diethylentriaminepentaacetic acid (DTPA) or
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) com-
pounds with anhydride, isothiocyanate, N-hydroxysuccinimide ester or
maleimide groups. Conjugation with a water-soluble polymer can in-
crease the agent relaxivity, improve stability in the blood, and limit
agent extravasation from the healthy endothelium. The size of water-
soluble polymer derivatives is generally larger than that of low-
molecular-weight compounds but smaller than that of nanoparticles.
Polymer-basedMRI contrast agents can be applied tomolecular imaging
of various diseases by modifying site-speciﬁcity or functional moieties.
In this section, we discuss basic properties of several polymer-
based MRI contrast agents, which are described in more detail in other
reviews [6,35].
3.2. Natural polymer-based contrast agents
Human serum albumin is the most abundant protein in the blood,
with a molecular weight of 66,500 [36]. Albumin-Gd can be used to de-
termine blood plasma volume [37], capillary permeability [38], extent of
inﬂammation [39], and presence of tumor malignancy [40]. Although
albumin-Gd has been widely used in preclinical research, instability
during heat sterilization, immunogenicity, and slow clearance have
hindered its clinical use [41,42]. Several Gd-DTPA derivatives with low
molecular-weights, non-covalently bound to endogenous blood albu-
min, have been developed to solve this problem [43].
Antibodies have advantages over other polymers in strong, speciﬁc
binding to an antigen. Various antibody fragments, such as F(ab′),
F(ab′)2, Fab or single chain variable fragments (scFv), can be prepared
through chemical, biological, and recombinant genetic methods [44].
Antibody-based contrast agents have been developed using a prepara-
tion technique for antibody-labeled radioactive probes [45]. However,
an overabundance of chelates conjugated to the antibody may cause a
drastic reduction in immunoreactivity [46]. Thus, water-soluble poly-
mers, (e.g. Poly-L-lysine (PLL)), that incorporate a number of Gd3+
have been carefully optimized to achieve better signal enhancement
withminimal reduction in immunoreactivity [47,48]. In addition to anti-
bodies, aptamer-based contrast agents have been designed for targeting
contrast agents to tumor tissue [49] or sensing small molecules [50].
Fig. 3. Representative structures of water-soluble polymer-based contrast agents for MRI. A. Linear (left) or branched (right) polymers are used for preparation of water-soluble polymer-
based contrast agents. B. Targeted water-soluble polymer-based contrast agent. C. Multimodal water-soluble polymer-based contrast agent. D. Theranostic water-soluble polymer-based
contrast agent.
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amino and carboxyl groups of lysine. PLL-Gd can be formed by reacting
the anhydride or N-hydroxysuccinimide ester groups-bearing DTPA or
DOTA to the amino groups of PLL, followed by labeling with Gd3+.
PLL-Gd has been used in the blood to evaluate the ischemic state of
the myocardium [51] and the disease state of lung [52]. PLL-Gd has
also been used to visualize tumor tissue because of its accumulation
due to the EPR effect [53].
Polysaccharides are a major component of many biological struc-
tures, such as the cell wall of plants, the exoskeleton of arthropods,
the connective tissue and cell surface of mammalian cells. They also
serve as a source of energy. The immunogenicity of polysaccharides is
generally lower than that of proteins. When administered intravenous-
ly, polysaccharides are metabolized and excreted by glomerular ﬁltra-
tion. Several polysaccharides, such as pullulan [54,55], mannan [56] or
hyaluronic acid [57], can be recognized by cell surface receptors. This bi-
ological recognition not only permits the receptor-speciﬁc targeting of
agents to the cell, but also accelerates cellular internalization through
receptor-mediated endocytosis. Polysaccharides of various molecular
weights can be obtained commercially. Most polysaccharide-based MR
contrast agents are obtained by attaching functional groups to reactive
chelate residues, followed by labeling with Gd3+.
Dextran is an α-1,6-glucan of low immunogenicity. Lowmolecular-
weight dextran (75,000 ± 25,000) is used clinically as a plasma
expander [58]. Dextran can be conjugated through hydroxyl groups
(by ester bond formation) [59] or through amino groups after reaction
with a diamine linker (by amide or thiourea bond formation) [60].
Dextran-Gd has been used inMR angiography [61], microscopic embry-
onic cellular imaging [62], and investigations associated with acute
myocardial infarction [63] and cardiac perfusion [64]. MR contrast
agents prepared from other polysaccharides such as chitosan [65], inu-
lin [66], starch, or their derivatives [67], have also been reported.
3.3. Synthetic polymer-based contrast agents
Synthetic polymers can be created with a narrow molecular
weight distribution, and they can be developed to exhibit minimal im-
munogenicity and high physiological speciﬁcity. There are two ap-
proaches to preparing synthetic, polymer-based contrast agents. Oneis to chemically conjugate the MR probe to a pre-synthesized polymer.
The other is to polymerize monomers that are already bound to the
MR probe. Linear and globular polymers are obtained by different
types of polymerization methods and monomer structures.
PEGmolecules are linear polymers that arewidely availablewith dif-
ferent molecular weights and reactive groups. PEG-based contrast
agents (e.g. PEG-Gd) can be created by chemically conjugating a PEG-
amine to an amino-reactive chelate residue. Other linear polymers,
such as a polyaspartate of a synthetic polypeptide [68] or a polymer
[69] synthesized by ring-opening metathesis polymerization, have
been developed and conjugated. Condensation between DTPA anhy-
dride and diamines also enables the synthesis of polymerswith the che-
late residue in themain chain. This condensationmethod gives different
polymer structures by changing diamine properties. In addition to
synthetic polymer-based contrast agents based on Gd3+, a synthetic
polymer modiﬁed with Eu3+ has also been developed for chemical ex-
change saturation transfer (CEST) imaging [70].
Dendrimers are themostwidely and systematically studied globular
polymers that are used as MRI contrast agents. There are two basic ap-
proaches to forming dendrimers; one is a convergent approach in
which the branches are constructed separately and later bound to a cen-
tral core. The other is a divergent approach, inwhich thepreparation be-
gins from the core and grows stepwise outward. A variety of dendrimers
can be formed by changing the chemical structure of the core, varying
the coupling agents, and by altering the branch number. Dendrimer-
based MR contrast agents can be formed by reacting amine groups on
the dendrimer with reactive chelates. In one such formulation, the
relaxivity of dendrimer-Gdwas higher than that of Gd-DTPA [71]. In ad-
dition, the biodistribution of dendrimer-Gd was modulated by the
generation number (size) [72], and by the core structure [73]. In addi-
tion to dendrimer-Gd, ﬂuorinated- [74,75] and Mn2+-[76], Eu3+- or
Yb3+- modiﬁed dendrimers [77–79] have also been created for 19F MR
and CEST imaging, respectively.
3.4. Targeted polymer-based contrast agents
Functional ligands enableMRI probes to actively target to a site of in-
terest, resulting in local enhancement of MRI contrast. Many ligands,
such as antibodies [80,81], peptides [82,83], oligosaccharides [80,84],
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water-soluble polymers (Fig. 3B). Targeted, polymer-based MRI con-
trast agents can be used to image targets such as tumor, liver [84], and
cartilage [86]. We have developed a polymer-based MRI contrast
agent to image tissue regeneration after therapy [87]. Therapeutic an-
giogenesis is one of the most important technologies to treat ischemic
diseases and to support cell transplantation. We have created a
polysaccharide-based MRI contrast agent for the MRI-based evaluation
of therapeutic angiogenesis by chemical conjugation of dextran-Gd
with a cyclic peptide containing an arginine–glycine–aspartic acid se-
quence (cRGD) with an inherent afﬁnity for the αvβ3 integrin (cRGD-
dextran-Gd). The cRGD-dextran-Gd had an afﬁnity for cells expressing
the αvβ3 integrin and showed a high longitudinal relaxivity compared
to DTPA-Gd. The cRGD-dextran-Gd could be used after intravenous in-
jection to detect the ischemic–angiogenic region in mice with hindlimb
ischemia.
3.5. Polymer-based multimodal imaging
Multimodal contrast agents (Fig. 3C) can be created by conjugation
of other imaging probes with water-soluble polymer contrast
agents. Several groups have reported water-soluble polymer agents
for MRI and ﬂuorescence imaging [81,94]. It is possible to prepare mul-
timodal contrast agents by encapsulating polymer-based contrast
agents into other imaging probes. Shi et al. showed that gold nanoparti-
cles containing denderimer-Gd could be visualized using MRI and
CT [95].
4. Metal particle-based contrast agent
4.1. Overview
Magnetic nanoparticles have become important tools for molecular
detection and drug delivery. “Theranostic” agents combine these two
functions to deliver targeted therapy to a speciﬁc location. [98,99].
These agents can be combined a multifunctional or targeted nanoparti-
cles for a range of applications [98,100]. For MRI, the major use of mag-
netic nanoparticles is to shorten local water T2 or T1 through an
interaction between the electronic magnetic moments of the compo-
nent atoms of the nanoparticle and the nuclear magnetic moment of
the surrounding water. The strength of this interaction and the subse-
quent impact on the MRI signal is determined by many factors, includ-
ing the strength and localization of the magnetic moments of the
nanoparticle crystal and the access of water to the crystal core. Most
paramagnetic agents shorten both T1 and T2. However, agents
with strong coupling between component atoms tend to be detected
as T2-shortening agents, and paramagnetic atoms or chelates are typi-
cally detected as T1-shortening agents in normal concentrations. A com-
plicating factor is the fact that T1-shortening agents are often more
readily detected in the body because T1 of the tissue is longer, while
T2 agents tend to be more powerful (i.e. have higher relaxivity). The
basic mechanisms of MR relaxation in magnetic nanoparticles have
been extensively reviewed [101,102], though knowledge of nanoscale
magnetism is still incomplete.
Magnetic particle synthesis lies at the interface between chemistry
and physics. The chemistry involved can range from organic and bio-
chemical to inorganic, and it is crucial to understand how magnetism
is affected in these particles during synthesis. Some of the most recent
advances in magnetic nanoparticle synthesis have focused on tailoring
the properties of the nanoparticles to a speciﬁc application. This in-
volves control over both the physicochemical properties and the inter-
face between these properties and the instruments to detect or
activate the nanoparticles once they are at the target.
Superparamagnetic nanoparticles can be synthesized in a variety
of ways, ranging from physical pulverization of a large crystal [103], to
traditional chemical synthesis, to microwave synthesis. Chemicaltechniques inmetal crystal formation involve, broadly, either controlled
ionic bonding or oxidation around a small nucleated metal oxide, and
the formation can be performed in either gas- or aqueous phase. One
of the simplest, most widely-used techniques involves co-precipitation
of component metal salts. Thermal decomposition is also used, in
which metals are mixed into a heated surfactant to control particle ox-
idation, size, and shape. Recently microwave synthesis has also been
used to synthesize highly homogeneous, reproducible magnetic nano-
particles. Nanoparticle synthesis has been reviewed extensively in the
recent literature [104–106].
4.2. Superparamagnetic iron oxide-based nanoparticles
Some of the most common magnetic nanoparticles used in mo-
lecular and cellular MRI are formed from SPIOs and oxides of other
transition metals [30,107–115]. Because of the simplicity of synthe-
sis and good biocompatibility, many of the most ﬁrst commercial
iron oxides were dextran-coated, with an amorphous coating that
encompasses more than one particle. In recent years there have
been a number of new particles developed, both as passive and
targeted contrast agents.
Magnetic nanoparticles have been formed from other transition
metals, including manganese oxides and adsorbed composites of
Mn2+. Mn2+ has a higher average magnetic moment than does iron,
and is also readily oxidized to form a superparamagnetic crystal in a
nanoparticle. Several groups have developed manganese oxide nano-
particles, either as high-relaxivity T2-shortening contrast agents or as
agents that can dissociate upon intracellular release from an endosome.
In one proposed agent, Mn2+ dissociated from the crystal due to reduc-
tion in the low endosomal pH, allowing the change in MRI contrast to
report on intracellular delivery through a shift from T2- to T1-related
contrast [116].
Natural magnetic nanoparticles have been synthesized from
biologically-derived macromolecules [117]. These nanoparticles can be
created to incorporate many of the properties of completely synthetic
nanoparticles, and the magnetism of these natural nanoparticles can
be readily controlled. Some examples of natural and endogenous mag-
netic nanoparticles are those formed from the cowpea virus [118],
magA [119], and from the iron storage protein ferritin [120–123]. Natu-
ral nanoparticles have some proposed advantages over other nanoparti-
cles in biocompatibility and ease of functionalization. Natural magnetic
nanoparticles may also prove to be useful “reporter” proteins formed
through endogenous native or recombinant expression and detection
with MRI. Thus, the development of natural nanoparticle contrast
agents is an active area of investigation.
One major goal of current research in MRI-detectable nano-
DDS and SPIO development is to increase the biocompatibility and
functionalization of these agents. Biocompatibility is important to both
preclinical and clinical translational work, and functionalization is im-
portant for agent targeting and stability after delivery. There has been
a great deal of recent work to develop nanoparticles with nontoxic or
biocompatible coatings [107,124–126]. Regulatory and practical guide-
lines for these types of studies are being identiﬁed as more researchers
aim to commercialize new agents or bring them to the clinic [127].
5. Quantum dot-based contrast agents
5.1. Overview
Over the last ten years, semiconductor QDs have been recognized as
a new type of optical imaging contrast agent because of their unique
spectral properties. These novel properties can be used to optimize
the signal-to-noise ratio, to improve the sensitivity of ﬂuorescence de-
tection, and to increase the quality of ﬂuorescent cellular andmolecular
imaging. Moreover, the size-tuneable ﬂuorescence emission and the
broad excitation spectra of QDs make it possible to use them in
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tracked for up to a few hours with ﬂuorescence confocal microscopy
[128], total internal reﬂection microscopy [129], basic wide-ﬁeld
epiﬂuorescence microscopy [130], and single-molecule microscopy
[131]. QDs are also excellent probes for two-photon confocal microsco-
py [132] because they are characterized by a large absorption cross
section.
Since water-soluble QDs have many functional groups on their sur-
face, it is easy to conjugate them with biomolecules, (e.g. proteins,
DNAs, RNAs, small ligands, etc.), and other chemicals, (e.g., drugs)
(Fig. 4). The resulting conjugates combine the spectral characteristics
of the nanocrystal and the biomolecular functions of the attached bio-
molecules. The multi-functionality of QDs is one of the major advan-
tages of QDs over organic ﬂuorophores, for which conjugation is
usually restricted to one biocompatible molecule per dye molecule.
The large number (10 to 100) of potential surface attachment groups
can be used to confer different functionalities to individual QDs. For in-
stance, in addition to a recognition moiety, QDs can be equipped with a
membrane-crossing or cell-internalization capability, and/or an enzy-
matic function [133–135]. QDs are therefore appropriate matrices for
the development of novel drug carriers.
5.2. QD-based contrast agents
The architecture of water-soluble QDs allows also the development
ofmolecular probeswith dual- andmulti-modality imaging for simulta-
neous applications in optical imaging, MRI, PET, X-ray imaging, and
others [134–136]. The design and development of multifunctional and
multimodal imaging probes is limited in organic ﬂuorophores. Howev-
er, there are many reports of multimodal QD-based nanoparticles for
combined optical andMR imaging [134–142]. One type of nanoparticles
is created by the growth of heterostructures, in which a QD is either
overgrown with a layer of a magnetic material or linked to a
superparamagnetic or ferromagnetic nanoparticle. A second type is cre-
ated by incorporating paramagnetic ions into the QDs. A third type is
created using silica or polymer nanoparticles as a matrix for the incor-
poration of both QDs and magnetic nanoparticles. Finally, a fourthFig. 4. Schematic structure of multimodal QD probes. (A) QDs for target-speciﬁc interaction us
silica sphere has QDs and paramagnetic nanoparticles inside and target-speciﬁc groups attache
silica-shelled single-QD micelles (Bakalova et al. [136]). Copyright (2007) Naure Photonics.type is created by chelating molecules with paramagnetic ions into the
coordination shell of the QDs. All different approaches have led to
breakthroughs in bioimaging and image-guided drug delivery [143].6. Vesicle-based contrast agent
6.1. Overview
Vesicle-based nanoparticles contain membranes with an interior
aqueous phase formed through self-assembly. Generally, hydrophobic
interactions between amphiphilic substances form a driving force for
the self-assembly. Electrostatic interactions can also drive assembly, as
demonstrated by the recent demonstration of polyion complex vesicles
(PICsomes) [153]. There are two types of hydrophobic interaction-
based vesicles; polymersomes formed from polymers and liposomes
formed from amphiphilic lipids. Since there are only a few reported ex-
amples of polymersome-based contrast agents [154–156], wewill focus
primarily on the current status of liposome-based contrast agents.
Liposomes have advantages over other carriers, including ease of
preparation, simplicity of materials, ease of size control and surface
modiﬁcation, and the presence of an interior aqueous phase. Liposomes
have had a long history of use in drug delivery. Liposomes can incorpo-
rate and maintain the function of various bioactive substances such as
low-molecular-weight drugs, peptides, proteins, and nucleic acids. The
liposomal surface can be readily modiﬁed by the derivatization of the
lipids. For example, the liposome can be functionalized with PEG by
conjugating PEG to the component lipids. PEGylated liposomes can es-
cape recognition by the reticuloendothelial system, resulting in en-
hanced retention in the blood circulation and accumulation in the
tumor tissue through the EPR effect. Doxil™, a PEGylated liposome in-
corporating doxorubicin, has been approved as a drug for cancer treat-
ment. In addition, there have been a number of reports of smart
liposomes that degrade under various conditions such as changes in
pH [157,158], temperature [159], light [160], and ultrasound energy
[161,162]. In this section we introduce and discuss the current status
and future direction of liposome-based contrast agents for MRI.ing chelators (Michalet et al. [234]); (B) paramagnetic lipids (Mulder et al. [140]). (C) The
d to the outside (Wang et al. [139]). (D) The structure of a multimodal QD probe, based on
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Two approaches have been used to prepare liposome-based contrast
agents (Fig. 5A). One is to encapsulate the contrast agent into the inte-
rior aqueous phase of the liposome, and the other is to attach the MRI
probe to the liposomemembrane.Water-solubleMRI probes can be en-
capsulated in liposomes by the addition of an aqueous solution contain-
ing the MR probe onto to a thin ﬁlm of lipid. These types of complexes
have been formed with chelates of Mn2+ or Gd3+. The relaxivity of
theMR probes has increasedwith encapsulation into the interior of a li-
posome, also depending on liposome size, membrane composition, and
water-membrane permeability. TheMRI probe can be attached to the li-
posome surface using lipids chemically conjugated with the chelate
complex on the hydrophilic head. The relaxivity of an MRI probe at-
tached to a liposome surface appears to be about six to seven times
higher than that of free MRI probes, regardless of liposome size [163].
Unmodiﬁed liposomes tend to accumulate in the liver and spleen
due to recognition by the reticuloendothelial system. PEGylation can
be used to avoid this and increase the blood lifetime of the agent. Be-
cause of this, liposome-based contrast agents can be used to visualize
ﬁne vasculature [164,165] (Fig. 1). On the other hand, the long lifetimes
of liposome-based contrast agents in the blood can be problematic due
to possible decomplexation of Gd3+-chelate and release Gd3+ from the
liposomes [166]. Furthermore, nanoparticles with size of 100–150 nm
cannot be reliably delivered to the center of a tumor in the presence
of the stromal barrier [167]. The liposomal structure must therefore be
modiﬁed to increase clearance rate and effectively target the site of in-
terest. In the case of MR probes encapsulated into liposomes, the mem-
brane of the liposomemust break and release the MRI probe. Stimulus-
responsive liposomes [168] have been developed using this strategy. In
the case of MRI probes attached to a liposome surface, the cleavable
bond can be inserted between chelate complex and the lipid. Kabalka
et al. synthesized conjugated lipids with amide, ester, or disulﬁde
bonds between the chelate complex and the lipid before forming the li-
posomes [9].
6.3. Targeted liposome-based contrast agent
The attachment of targeting ligands to a surface enables delivery of a
liposome to a site of interest (Fig. 5B). Antibodies, peptides, andpolysac-
charides have been used as targeting ligands. Two types of modiﬁcationFig. 5. Representative structures of liposome-based contrast agents forMRI. A. Two approaches t
ous phase of liposome (left) and modiﬁcation of MRI probes onto the liposome membrane (r
agent. D. Theranostic liposome-based contrast agent.methods have been reported [12]; one involves covalent coupling to
lipids such as thiol-maleimide coupling, and the other involves a specif-
ic, non-covalent interaction with the lipid. There have been many re-
ports of targeted liposome-based contrast agents to visualize diseases
such as inﬂammation [169,170], tumor angiogenesis [171,172], tumor
cells [173], and atherosclerosis [174,175].
7. Polymeric micelles-based contrast agent
7.1. Overview
Polymeric micelles are self-assemblies of amphiphilic block copoly-
mers consisting of water-soluble and hydrophobic segments in a bio-
compatible shell. Polymeric micelles form a core for drug loading
(Fig. 6A) [7,185,186]. The cores of polymeric micelles can be designed
to incorporate a variety of reporters and biomolecules, including
hydrophobic drugs [187],metal complexes [188,189], and chargedmac-
romolecules [190] such as nucleic acids, by engineering the core-
forming backbone. Polymeric micelles present several advantages as
nanocarriers, including prolonged blood circulation and a size range be-
tween 10 and 100 nm. This size range is useful for evading nonspeciﬁc
uptake by the reticuloendothelial system, avoiding renal excretion, con-
trolling drug release, and recognizing molecular targets with surface li-
gands [191]. Moreover, after controlled dissociation of the micelles, the
block copolymers forming the micelles can be eliminated by the kid-
neys. By functionalization of the surface of these micelles with ligands
to cell-speciﬁc surface receptors, they can possess cellular selectivity
and superior intracellular delivery [191]. Antibodies [192], fragments
of antibodies [193], aptamers [194], peptides [195,196] and small mole-
cules [197] have been used as ligands to improve the tumor targeting
ability of micelles (Fig. 6A). Micelles can also be designed to respond
to internal stimuli such as pH, reductive environment, and enzymes
[7,185,186], or external stimuli including light and ultrasound [198,
199] to enhance their speciﬁcity to malignant tissues.
Due to the prolonged blood circulation of polymeric micelles and
their small size, polymeric micelles have been shown to penetrate and
accumulate in solid tumors due to the EPR effect, enhancing the antitu-
mor activity of the incorporated molecules. Several polymeric micelle
formulations incorporating the anticancer drugs doxorubicin, paclitaxel,
SN-38, cisplatin, and (1,2-diaminocyclohexane)platinum(II) (DACHPt,
activated oxaliplatin) have advanced to clinical trials [200,201].o prepare liposome-based contrast agents; encapsulation ofMRI probes into interior aque-
ight). B. Targeted liposome-based contrast agent. C. Multimodal liposome-based contrast
Fig. 6. A. Polymeric micelles are core-shell assemblies of amphiphilic block copolymers, forming a biocompatible shell and a core for incorporating reporters and therapeutic molecules.
Tissue-speciﬁc ligands can be installed in the surface of themicelles to improve their targeting efﬁciency. B.MRI-functionality can be introduced by conjugating contrast agents at the end-
group of the hydrophilic segment of the block copolymers, facilitating thewater-exchange of the contrast agent after self-assembly. C. By loading theMRI-contrast agents in the core, high
payloads can be incorporated in polymeric micelles.
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Polymeric micelles can also be applied to deliver MRI contrast
agents, selectively enhancing the contrast of tumor and other tissues
and improving the efﬁciency of diagnosis. Because the micelle-
forming block copolymers can be readily engineered to incorporate
MRI contrast agents, several types of micelles have been recently devel-
oped for contrast-enhanced MRI. Paramagnetic metal-chelates, such as
Gd3+ and Mn2+, have been introduced into micelles to create MR posi-
tive (T1-shortening) contrast agents [65,202–204], while iron oxide par-
ticles have been incorporated in micelles as T2-shortening contrast
agents [205].
While the installation on the PEG end allows only a single T1-
shortening contrast agent per polymer (Fig. 6B), loading contrast agents
in the core can increase the number of contrast agents per polymer
(Fig. 6C). Moreover, the relaxivity of incorporated contrast agents can
be modulated by controlling their location in the micelles. Thus, while
the conjugation of Gd-based contrast agents to polymers usually in-
creases relaxivity due to a decrease in the rotational correlation time
[206], the position of conjugation will determine the ﬁnal relaxivity of
the micelles. Accordingly, by conjugating contrast agents on the end of
the hydrophilic block that forms the shell of the micelles, the relaxivity
will be maintained even after micelle formation because water can
readily access the contrast agent [202,203,207]. Conversely, the
relaxivity of the contrast agents introduced in the core-forming block
of the micelles will drop when the penetration of water to the hydro-
phobic core is limited [208–210]. For example, PEG-b-PLL copolymers
covalently bound to Gd-DOTA in the PLL backbone decreased in
relaxivity from about 10 mM−1 s−1 to 2 mM−1 s−1 after self-
assembling into polymeric micelles [209,210].When bound to clinically approved Gd-chelates that are released
and allowed to clear through the kidneys, polymeric micelles can be a
safe and non-toxic platform for diagnosis. Nevertheless, covalently
linking Gd-chelates to the polymers forming the micelles can extend
the residence time of the Gd-chelates in the body, possibly increasing
the risk of release of toxic Gd3+ by transmetallation [211–213]. More-
over, if these Gd-chelates are internalized in cells, toxic Gd3+may be re-
leased because of the reduced stability of the chelate at acidic
endosomal pH. Thus, there are several approaches to forming micelles
without covalent conjugation to permit earlier release of the contrast
agents. One approach is to introduce a hydrophobic moiety onto the
Gd-chelate, forming an amphiphilic contrast agent [202,203,208,214,
215]. For example, Trubetskoy et al. incorporated amphiphilic Gd-
DTPA-phosphatidylethanolamine (Gd-DTPA-PE) into the hydrophobic
core of micelles prepared form PEG-phosphatidylethanolamine [216].
The lipid component of this contrast agent was assembled at the core
of the micelles, while the hydrophilic Gd-DTPA was exposed at the sur-
face of the core towards the PEG shell, increasing the relaxivity to
17 mM−1 s−1 [216]. However, lipid-modiﬁed Gd-chelates have not
been clinically approved. Gd-chelates can be incorporated in polymeric
micelles for clinical use with a reversible bond between the contrast
agent and the polymer [215,217].Wehave recently proposed polymeric
micelles incorporating Gd-DTPA in the core through reversible com-
plexation of the carboxylic group of Gd-DTPAwith Pt4+ thatwere stably
bound to the amine groups of a PEG-b-poly [N-[N′-(2-aminoethyl)-2-
aminoethyl]aspartamide] (PEG-b-PAsp(DET)) copolymer [217]. Gd-
DTPA was gradually released from the micelles in a chloride-
containing medium by the ligand exchange reaction of Pt4+ from the
carboxyl group of Gd-DTPA to the chloride ions. Even though Gd-
DTPA was not covalently linked in these supramolecular structures,
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Manganese (Mn) has also been considered a safe alternative to Gd3+
in constructing T1-shortening polymeric micelles [218]. Polymeric mi-
celles can be created by incorporating manganese oxide in the core of
the micelles for Mn-enhanced MRI [107]. These micelles create pH-
sensitive MRI contrast because the manganese oxide nanoparticles re-
lease free Mn2+ at the acidic pH of ~5 in the endosome. Relaxivity is
also increased whenMn2+ is complexedwith a protein [107]. In anoth-
er approach, Jang et al. have developed polymeric micelles by self-
assembly of amphiphilic PEG-Mn(III)-porphyrin polymers [219]. These
agents are potentially useful as T1-shortening contrast agents.
Iron oxide nanoparticles have been incorporated in different micelle
formulations to prolong residence time in the blood and increase accu-
mulation in solid tumors. Kataoka et al. used PEG-b-poly(α,β-aspartic
acid) (PEG-b-P(Asp)) to load β-FeOOH nanoparticles in the core of
polymeric micelles (Fig. 7A) [220,221]. The carboxylic moieties in
PEG-b-P(Asp) formed stable monodentate-complexes with the Fe
atomson the surface ofβ-FeOOHnanoparticles, protecting thenanopar-
ticles with a dense PEG shell and improving agent stability in
the circulation [220]. These micelles speciﬁcally enhanced tumor
contrast in subcutaneous murine colon adenocarcinoma Colon-26
(Fig. 7B) [220] and human BxPC3 pancreatic tumor models [221]. SPIO
nanoparticles have also been incorporated inmicelleswith hydrophobic
core-forming backbones, such as, PEG-b-poly[N-(2-hydroxypropyl)
methacrylamide dilactate] [222], PEG-b-poly(Lactic acid) [223] and
PEG-b-poly(caprolactone) [224] copolymers. Since the SPIO nanoparti-
cles clustering in the core of the micelles dephases the spins of neigh-
boring water protons to increase the T2 relaxivity of the nanoparticles,
the tumor-speciﬁc contrast of these micelles can be achieved in quite
low concentrations.
Fluorine-containing polymers have also been used to create self-
assembling polymeric micelles. 19F has low background and it can be
detected with conventional clinical MRI systems [225]. Nagasaki et al.
has reported smart core-shell nanogels containing 2,2,2-triﬂuoroethyl
methacrylate in the core. The hydrophobicity of the core-forming poly-
amides can be controlled such that the resulting the MRI signal can re-
port on local pH. At physiological pH (7.4 pH), the MR signal is low
because the nanogel core is hydrophobic and water cannot interactFig. 7.A. Self-assembly of polymericmicelles from PEG-b-poly(α,β-aspartic acid) (PEG-b-P(Asp
PEG-b-P(Asp) formed stable monodentate-complexes with the Fe atoms on the surface of β-Fe
image of the PEG-P(Asp)-coated β-FeOOH nanoparticles indicated a core-shell structure of app
subcutaneous murine colon adenocarcinoma Colon-26 tumor before and 3 h after the injectionwith 19F. At intratumoral pH, (~6.5 pH), the core becomes hydrophilic,
increasing the intensity of the 19F-MR signal [226].
7.3. Micelles for multimodal imaging
MRI allows high spatial resolution but lacks the sensitivity of other
imaging modalities. Improved visualization of the tissue morphology
and function can be achieved by developing a contrast agent that is de-
tectable by several imaging modalities. For example, ﬂuorescence and
PET reporters have been successfully combined with MRI contrast
agents.
Combining MRI and ﬂuorescence agents is useful for visualizing the
distribution of polymericmicelles in conjunctionwith tissuemorpholo-
gy. MRI can provide high spatial resolution throughout the body and
also provide information on the function and microdistribution of the
micelles, while intravitalmicroscopy can provide complementary infor-
mation at the cellular and subcellular level [227]. Several methods have
been used to merge these two imaging modalities. While MRI contrast
agents can be incorporated into polymeric micelles as described in the
previous section, ﬂuorescence can be introduced by incorporation of
QDs in the core of the micelles [228,229] or by conjugating ﬂuorescent
probes to the micelle to form block copolymers [230,231]. Because of
the limited penetration of light in living tissues, ﬂuorophores with
long emission wavelengths in the NIR region are generally preferred
for developing multimodal micelles [232]. Moreover, because the
ﬂuorescent signal of several dyes and QDs can be quenched or trans-
formed by Förster resonance energy transfer (FRET) in a controllable
manner [16,233–235], optical probes in micellar systems can be used
as reporter systems that respond to a speciﬁc stimulus. This is the case
for pH-sensitive polymeric micelles prepared from a PEG-b-poly(2-
(diisopropylamino)ethyl methacrylate) copolymer covalently bound
to Gd-DOTA and nitrobenzoxadiazole ﬂuorophores in the cores, creat-
ing pH-triggered enhancement of signal intensities for both imaging
modalities [236]. At pH 7.4, the exchange between Gd-DOTAmolecules
and water is not enough to provide a high MR signal, and the
nitrobenzoxadiazole molecules in the core are quenched. At pH 5.0,
the cross-linked poly(2-(diisopropylamino)ethyl methacrylate) cores
become hydrophilic due to the protonation of the tertiary amine resi-
dues, permitting access of water molecules to Gd-DOTA and)) and β-FeOOHnanoparticles in the core of polymericmicelles. The carboxylicmoieites in
OOH nanoparticles. Energy-ﬁltering transmission electron microscopy (EFTEM) zero-loss
roximately 60 nm. B. T2-weighted images at 4.7 T and T2 color maps of a mouse bearing a
of PEG-P(Asp)-β-FeOOH micelles. Adapted from Ref. [220].
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shortening polymeric micelles were also prepared from PEG-b-poly(β-
amino ester) copolymers with ionizable tertiary amine groups having
Sulforhodamine 101 bound to the poly(β-amino ester) backbone
[237]. The polymeric micelles encapsulated SPIO nanoparticles at phys-
iological pH 7.4, enhancing the relaxivity of the nanoparticles to more
than 250 mM−1 s−1. At pH 7.4, the ﬂuorescence of Sulforhodamine
101 was quenched by energy transfer. At pH 6.8–7.0, the ﬂuorescent
signal was recovered, suggesting the potential use of these micelles as
pH-triggered reporters of acidic biological environments.
Polymeric micelles can also be used to combine the high anatomic
resolution of MRI with the highly sensitive imaging of PET. Due to the
difference in sensitivity between these imaging modalities, the detect-
able concentrations of MRI contrast agents should be much higher
than those of PET probes. Thus, polymericmicelles offer unique features
for combining high-loads of MRI contrast agents in their cores and pre-
cise amounts of PET probes on the surface of the PEG shell. For example,
SPIO nanoparticles coated with PEG-phospholipids, having a DOTA che-
lator at the PEG-end, were labeled with 64Cu [238].68Ga has also been
combined with SPIO nanoparticles within the same polymeric micelle.
These micelles were prepared by self-assembly of PEG-b-poly(lactic-
co-glycolic acid), with SPIO nanoparticles incorporated in the hydro-
phobic core of the micelles and 68Ga installed on surface of the PEG
shell of the micelles after chelation with 2,2′-(7-(4-((2-aminoethyl)
amino)-1-carboxy-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid
(NODA) [239]. Both 64Cu and 68Ga allowed the precise study of the
biodistribution of the micelles by PET.
8. Contrast agents based on other nanoparticles
8.1. PLGA-based contrast agents
Nanoparticles prepared from water-insoluble polymers, such as
poly(lactide-co-glycolide) (PLGA), can be used as contrast agents.
Both hydrophobic and hydrophilic drugs can be incorporated into the
polymeric nanoparticles by forming oil-in-water and water-in-oil-in-
water emulsions. Several types of contrast agents with activatable
[107], multimodal [13,251] or theranostic [252] capabilities have been
prepared by using these containers. In addition, chemical conjugation
of amphiphilic substances has been used to stabilize polymeric nano-
particles and provide surface modiﬁcation [253].
8.2. Silica-based contrast agents
Silica-based contrast agents have been also extensively investigated.
Almost all silica-based contrast agents are prepared from silica nanopar-
ticles. There are two main types of silica-based nanoparticles [254],
namely solid silica and mesoporous silica. Solid silica nanoparticles
can be prepared by the hydrolysis of a silicon alkoxide precursor,
(through a sol–gel process), in ethanol and water (Stöber method), or
inside the water phase of an emulsion in oil (through the reverse
microemulsion method). Mesoporous silica nanoparticles can be ob-
tained by a surfactant-templated sol–gel reaction. Advantages of silica
nanoparticles include ease of preparation, biocompatibility, and even
dispersion in water. Since silica nanoparticles neither absorb light nor
perturb a magnetic ﬁeld, silica-based contrast agents can be combined
with probes through the well-established siloxane chemistry. Silica-
based T1-shortening MRI contrast agents have been prepared by bind-
ing Gd-chelated trialkoxysilane derivatives to the surface of solid [255]
or mesoporous silica nanoparticles [256]. Silica-based, T2-shortening
MRI contrast agents have been prepared by the encapsulating the iron
oxide nanoparticle in the silica matrix [257]. Other structural types of
silica-based MRI contrast agents based on a polyhedral oligomeric
silsesquioxane (POSS)-core dendrimer has been developed by Tanaka
et al. [258]. The high relaxivity of a POSS-based MRI positive contrastagent was achieved by the addition of Gd-chelated derivatives on the
rigid cubic structure.
9. Responsive (activatable) contrast agents
Several types of small-molecule, chelate-based responsive agents
have been reported [259], such as enzyme-activated (beta-galactosi-
dase) [260], Ca2+ concentration-activated [261] and pH-activated
[262,263] agents. In this section, we highlight several polymer- or
nanoparticle-based responsive or activatable contrast agents for MRI.
9.1. Polymer-based responsive and biodegradable contrast agents
Polymer-based MRI contrast agents have been modiﬁed for
improved biodegradability and rapid excretion. It is known that
disulﬁde bonds are broken down by thiol-bearing compounds present
in the body [88]. Therefore, polymers containing disulﬁde bonds
(polydisulﬁdes) enable MR probes to be rapidly excreted due to poly-
mer degradation, resulting in enhanced contrastwhere the probes accu-
mulate. Several polydisulﬁdes of linear polymers [89] or dendrimers
[90,91] have been reported.
There are a few reports on activatable MRI probes prepared by
water-soluble polymers. Sherry et al. reported that the relaxivity change
of a pH-responsiveMRI probewas enhanced by attachment to a dendri-
mer [92]. Lu et al. developed a Gd3+-DNA strand conjugated to a DNA
aptamer for adenosine [50]. When bound to adenosine, the conjugate
dissociates to release the Gd3+ containing-DNA strand, which de-
creased MRI contrast due to a reduction in relaxivity. Kikuchi et al. de-
veloped activatable MRI probes using pH-responsive polymers [93]. A
decrease in pH made the morphology of the polymer change from ex-
panded to shrunken, resulting in increased relaxivity.
9.2. Nanoparticle-based responsive contrast agents
9.2.1. Functional metal particle-based responsive contrast agents
Several groups have investigated new approaches to chemical SPIO
synthesis to impart speciﬁc functions to the nanoparticles in situ. One
example of this is the development of a “switchable”magnetic nanopar-
ticle, activated by light. [264]. Another example is the use of chemical
doping to tune MRI contrast (r1 vs. r2) in a nanoparticle of a uniform
size [265]. Finally, nanoparticles (~100 s of nm in size) have been creat-
ed through stereolithography with deﬁned shapes that enable them to
be distinguished from each other [266].
Magnetic particle imaging has also emerged as a potentially impor-
tant imaging modality, based on the direct detection of magnetic parti-
cles in three dimensions [267]. Magnetic particles can be used as
theranostic agents through combinedMRI-based detection and local tis-
sue heating with radiofrequency energy [268]. While it can be difﬁcult
to directly functionalize metals in a crystal, many magnetic particles
are readily encapsulated in either synthetic or natural coatings.
9.2.2. Functional QD-based responsive contrast agents
QDs are also potential photosensitizers. QDs are energy donors,
based on triplet resonance energy transfer and/or FRET [141]. Energy
transfer between QDs and other intracellular molecules such as triplet
oxygen, reducing equivalents, and pigments, could induce the genera-
tion of reactive oxygen species and reactive nitrogen species, invoking
apoptosis and necrosis in cells. Several recent papers suggest that cyto-
toxicity of QDs, mediated by light irradiation, might be used to kill can-
cer cells [144–146]. The light-mediated cytotoxicity of QDs, combined
with their capacity as energy donors, has enabled the application
of QDs as novel photosensitizers or cofactors of conventional
photosensitizing agents used in photodynamic therapy (PDT). This ap-
plication was ﬁrst described in 2004 [147]. Since then, many groups
have published in this area [148–152]. A signiﬁcant beneﬁt of QDs is
that they can be precisely tuned by changing their size and composition.
86 K.M. Bennett et al. / Advanced Drug Delivery Reviews 74 (2014) 75–94The optical emission of QDs results from quantum-conﬁnement effects
and can be tuned to emit from the ultraviolet to the near infrared
(NIR) spectral regions, in contrast to the largely visible emission of
most conventional photosensitizers. Because there isminimal light scat-
tering and absorption in the NIR region of the spectrum, light of low in-
tensity can be used to penetrate tissue to depths of several centimeters,
allowing access to deep-seated tumors. Furthermore, because of their
large transition dipole moment, QDs are strong optical absorbers, mak-
ing them potential drugs for photodynamic therapy.9.2.3. Functional liposome-based responsive contrast agents
Activatable liposome-based contrast agents can be created based on
the structural change of the MRI probe in the liposome. Aime et al.
prepared a pH-sensitive amphiphilic Gd3+ complex and loaded into li-
posomes [176]. The Gd3+ complex was reversibly changed from hydro-
philic to hydrophobic based on pH, which affected the structure and
intraliposomal distribution of the complex. As a result, the relaxivity
was altered with pH due to the difference of complex status in the
liposome. It is also possible to change relaxivity by a change in the
molecular weight of an MRI probe. This can be used to form an
activatable liposome-based MRI contrast agent sensitive to the reduc-
tive environment [177]. Skurtveit et al. incorporated Gadofosveset, a
low-molecular-weight Gd-chelate with high afﬁnity for albumin, into
pH-responsive liposome [178]. The relaxivity of the liposome agent in-
creased at low pH in blood due to the increase in apparent molecular
weight of Gadofosveset that was released and bound to albumin.
Liposome-based contrast agents can incorporate many other imag-
ing agents. Since liposomes have an interior aqueous phase and reactive
membrane, various types of multimodal liposome-based contrast
agents have been reported [12,179] (Fig. 5C). Tabor et al. created amul-
timodal liposome-based contrast agent composed of lipid conjugated
with chelate complex of Gd3+, 64Cu2+ or 111In3+ and ﬂuorescent dye,
modiﬁed with PEG. This multimodal liposome was visualized by MRI,
SPECT, and optical imaging, and the biodistribution and blood half-life
were similar to those of an unmodiﬁed PEGylated-liposome [180]. A
multimodal liposome containing iohexol and gadoteridol was also re-
ported for both MRI and CT [181].10. Theranostic applications in tumor imaging and therapy
Theranostics is a portmanteau of therapeutics and diagnostics.
Nano-DDSwith contrast agents can easily and closely link to theranostic
applications. In addition, because nano-carbon is excellent theranostic
materials based on the ROS generation capability, nano carbon-based
contrast agents are also discussed here.10.1. Polymer-based theranostic applications in tumors
Theranostic agents (Fig. 3D) can be created by attaching therapeutic
molecules andMRI probes to water-soluble polymers. Ghandehari et al.
formed a theranostic agent by conjugatingGd-DOTA and doxorubicin to
N-(2-hydroxypropyl)methacrylamide copolymer [96]. In the sameway,
cisplatin and gadolinium chelate were conjugated to gelatin for tumor
theranostics [269]. Reineke et al. developed polymer beacons for lumi-
nescence imaging and MRI of DNA delivery by conjugating chelate res-
idue with polycation, which enables them not only to bind Eu3+ and
Gd3+ but also to complexwith DNA through an electrostatic interaction
[97]. They conﬁrmed dual imaging and effective DNA delivery into cul-
tured cells. Lu et al. prepared PEGylated poly-(L-glutamic acid) conju-
gates containing mesochlorin e6, a photosensitizer, and Gd-DOTA, and
demonstrated photodynamic therapy based on contrast-enhanced
MRI [270]. In addition, gel-based nanoparticles (nanogel) are potential-
ly applicable as biocompatible theranostic agents for PDT [271–273].10.2. QD-based theranostic applications in tumors
It is difﬁcult to develop QDs as both diagnostic and therapeutic
agents because of the fundamental difference in the structure of the
nanoparticles needed to ensure high image contrast and the photody-
namic effect. For imaging diagnostics, the core nanocrystal has to be
coated by a solid organic or inorganic coat and conjugated by target-
speciﬁc ligands and inert polymers. For PDT, the core nanocrystal has
to be naked to ensure energy transfer to other intracellular organicmol-
ecules and light-mediated cytotoxicity. Currently, theranostic applica-
tions of QDs are limited because of the risk of heavy metal-induced
toxicity. However, the development of graphene QDs may make them
more readily translated in the near future [274].
10.3. Liposome-based theranostic applications in tumors
Liposomes can be formed to simultaneously encapsulate various
types of compounds, such as low-molecular weight drugs, protein,
and nucleic acids to form theranostic agents (Fig. 5D). Bell et al. de-
signed liposome containing lipids conjugated with PEG, a ﬂuorescent
dye, surface Gd3+, and interior small interfering RNA. The liposome
was detected by MRI after accumulation in a tumor and reduced
tumor growth compared to the control liposome [275]. Bao et al. devel-
oped a multimodal and theranostic liposome with Gd3+, 64Cu2+, and a
NIR ﬂuorescent dye on the surface and 99mTc complex and doxorubicin
in the interior. The distribution of the liposome could be visualized by
MRI, NIR ﬂuorescent, PET and SPECT imaging after intratumoral admin-
istration [182].
Theranostic liposomes can also be made functional. Kono et al. pre-
pared a theranostic, thermo-sensitive liposome composed of a
thermosensitive polymer. The liposome incorporated lipids, conjugated
with PEG and a dendron-chelate-Gd complex on the surface and doxo-
rubicin in the interior. Accumulation of the liposomes in a tumor was
conﬁrmed by MRI after intravenous injection. Heating caused the re-
lease of the doxorubicin in the tumor tissue, resulting in therapeutic en-
hancement [11]. A thermosensitive PEGylated liposome encapsulating
Mn2+ for MRI contrast and doxorubicin was used to visualize tumor ac-
cumulation and temperature-triggered drug release [183,184].
10.4. Theranostic micelles
MRI can be used to detect the distribution of polymeric, therapeutic
micelles in speciﬁc tissues, and to follow the response to treatment in
real time [5]. In the clinic, theranostic micelles can be used to assess
the accuracy of therapy and provide early feedback on therapeutic
efﬁcacy.
Due to the low sensitivity of MRI, relatively high concentrations
of contrast agents can be required in theranostic micelles in clinical
use. By incorporating Gd-chelates into polymeric micelles, T1 relaxivity
can increase, reducing the concentration of Gd-chelates needed for
theranostic imaging. Taking advantage of the reversible complexation
of platinum and Gd-DTPA presented above, we have constructed
theranostic polymeric micelles that incorporate the parent complex of
the platinum anticancer drug, oxaliplatin, i.e. DACHPt, and Gd-DTPA to
follow the accumulation and efﬁcacy of the micelles in an orthotopic
model of intractable human pancreatic tumor (Fig. 8A) [8]. Conﬁning
Gd-DTPA in the core of these polymericmicelles increased the relaxivity
to 80.5 mM−1 s−1, which improved detection of solid tumors. These
theranostic micelles facilitatedmonitoring the biodistribution and ther-
apeutic effects of these micelles after accumulation in the tumor
(Fig. 8B) [8].
Theranostic self-assemblies have also been used in combination
with Mn-enhanced MRI. Examples include lipid micelles containing
manganese oxide nanoparticles and the anticancer drug doxorubicin
and/or plasmid DNA in their core [240], and self-assembled polymeric
toroids containing Mn-protoporphyrin complexes and anticancer
Fig. 8. A. Schematic diagram of the self-assembly of Gd-DTPA/DACHPt–loadedmicelles. Micelles are formed by the complex formation between the platinum drug and the poly(glutamic
acid) backbone of the copolymer. Gd-DTPA is incorporated in the core of the micelles by forming a similar complex. B. MRI at days 0 and 18 of a tumor-bearing mouse treated with Gd-
DTPA/DACHPt-loaded micelles. The tumor size was 89 mm3 at day 0 and 5 mm3 at day 18. Adapted from Ref. [8].
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clonal antibodies on the surface [241]. Both of these micellar systems
were theranostic in vitro.
T2-based contrast enhancement has also been generated from poly-
meric micelles for theranostics by introducing iron oxide nanoparticles
into micelles and incorporating various therapeutic molecules, such as
anticancer drugs [242–244], photosensitizers [245,246] and genes
[247–249]. These theranosticmicelles have been used to validate sever-
al delivery approaches in biological conditions by real-time monitoring
with MRI. Micelles prepared from ﬂuorinated polymers have also been
used as theranostic agents based on 19F-MRI, as recently reported for
polymeric micelles incorporating doxorubicin in their core [250].
10.5. Carbon-based theranostic contrast agents
10.5.1. Fullerene-based contrast agents
Fullerene-compounds combine therapeutic and imaging properties,
and are suitable for MRI-guided PDT, sonodynamic therapy (SDT), and
high-intensity focused ultrasound (HIFU) therapy. Fullerene (C60) is a
carbon nanomaterial with unique physical and chemical properties.
The attachment of PEG to C60 makes it water-soluble and allows
tumor targeting because of its EPR effect in tumor tissues [2,276].Additional conjugation of C60-PEG with chelators for paramagnetic
ions (Gd3+, Mn2+) allows the real-time observation of its pharmacoki-
netics with MRI. It has also been reported that water-soluble C60 gener-
ates ROS under light irradiation, making it a potential photosensitizer
for PDT [276,277]. In addition, ultrasound irradiation can activate C60
that has accumulated speciﬁcally in the tumor, facilitating and enhanc-
ing its antitumor activity [278,279]. To obtain maximum antitumor ef-
fects with PDT or SDT, light or ultrasound irradiation must be applied
when the concentration of C60-compound in the tumor region is
highest. Therefore, a non-invasive imaging technology is necessary to
determine when the concentration of photo/sono-sensitizing nanopar-
ticles in the tumor is adequate and also to evaluate therapeutic efﬁcacy.
Many factors, such as the sensitizing properties of C60, its accumula-
tion and retention speciﬁcally in the tumor, irradiation dose (strength,
depth, duration, time, frequency, and method), irradiated area, and
tumor characteristics, (e.g. type, growth, angioarchitectonic, tolerance,
and malignancy). These can all contribute to the effectiveness of a
PDT/SDT using fullerene-compounds. For C60-mediated PDT/SDT to be
effective, it is necessary to monitor or control these factors at each
phase of therapy. In particular, irradiation should be performed at the
exact time when the accumulation of fullerene photo- or sono-
sensitizer throughout the tumor reaches a maximum and while the
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PDT/SDT reports where image guidance was not available, the duration
of light or ultrasound irradiation has been arbitrarily decided [276,277,
280]. In image-guided studies, it is possible to select the duration of
the irradiation and to apply it when the concentration of photo- or
sono-sensitizer in the target tissue is maximal. For example, C60-Mn-
PEG and C60-Gd-PEG nanoclusters have enabled image-guided PDT or
SDT with non-invasive real-time monitoring of its accumulation in a
tumor and surrounding normal tissue [19,276]. They have also allowed
optimization of the irradiation duration and area. Dynamic T2- and
diffusion-weighted MRI have also provided real-time information
about edematous tissue damage, which is crucial to optimize the radia-
tion dose. Dynamic image-guided PDT and SDT are not only useful for
maximizing the therapeutic effects, but also for the development of
new photo- and sono-sensitizers that are highly efﬁcient generators of
ROS.
To obtain better contrast enhancement in MRI, fullerene derivatives
been developed with paramagnetic ions in the interior space of the ful-
lerene [18,281–284]. However, there is a tradeoff in these structures be-
tween the high relaxivity of the paramagnetic fullerene and its ability to
generate ROS. This depends on the synthesis procedure. It is important
to regulate the number of ligands and their orientation on the fullerene
surface. Surface modiﬁcation of the fullerene could result in a steric
screen of the carbon atoms, which can suppress its ability to be excited
by ultrasound (via a sonoluminescence-dependentmechanism) or laser
light.
Despite these limitations, fullerene-based multifunctional contrast
agents have many advantages over the widely used organic sono-
sensitizers such as porphyrin derivatives [19,285]. The porphyrins ﬂuo-
rescence possesses relatively low quantum yield. The pharmacodynam-
ics of porphyrins can be detected only by ﬂuorescent imaging, which is
rather limited for non-invasive deep-tissue visualization. It is therefore
extremely difﬁcult to optimize porphyrin tumor accumulation, antitu-
mor effects, and side-effects in vivo [286]. The photo- and sono-
sensitizers based on paramagnetic C60-compounds allow visualization
of their pharmacodynamics and optimization of their tumor accumula-
tion at the exact moment of light irradiation or ultrasonication. More-
over, T2- and diffusion-weighted MRI can provide information about
the status of the tumor tissue before and after PDT or SDT with C60-
compounds.
10.5.2. Carbon nanotube- and graphene-based contrast agent
Carbon nanotube (CNT)- and graphene-based compounds have also
attracted interest because of their possible application in image-guided
drug delivery using optical imaging, MRI, ultrasonography, PET, etc.
CNTs and graphene are composed of pure carbon, (similar to fuller-
enes), with atoms arranged cylindrically or in a regular linear hexagonal
pattern, respectively. These structures possess unique electrical, optical,
and mechanical properties because of their extremely high aspect ratio
(length/diameter ratio). They are excellent scaffolds for the develop-
ment of multimodal contrast agents with therapeutic potential.
The excellent electrical properties of CNT and graphene also allow
them to be extensively used in a wide range of biosensing platforms
[287,288]. Single-walled carbon nanotubes, (SWCNTs; with a typical
diameter of 1 nm and length of 100 to 400 nm), and graphene with all
carbon atoms exposed on their surfaces, exhibit ultra-high surface
area available for efﬁcient drug loading and bioconjugation for
theranostics [289–294]. Moreover, CNTs and graphene can penetrate
cell membranes without the toxic effects [295] seen with QDs.
CNTs have been used as optical imaging contrast agents as well
as PDT transducers for thermal ablation of cancer cells due to their efﬁ-
cient optical absorption and ﬂuorescence in the NIR spectrum
[296–298]. CNTs have also been used as T2-shortening MRI contrast
agents [299]. CNTs can be ﬁlled or coated with other contrast agents,
(e.g., ﬂuorophores and paramagnetic ions), to increase optical and MRI
contrast [298–300]. Thus, CNTs may serve as multimodal contrastprobes for simultaneous use in ﬂuorescence imaging, photothermal
optical coherent tomography, and MRI. CNTs also show promise for
use in ultrasonography. The size of the majority microbubble-based
ultrasound contrast agents (1–8 μm)makes them primarily intravascu-
lar ﬂow tracers. In contrast, the chemico-physical characteristics of
CNTs (e.g.100–400 nm in length),make thempotentially able to extrav-
asate and reach a target area through vascular pore sizes up to 780 nm
[289,301].
Ultrasound contrast agents are classiﬁed as long half-life agents
when the signal persists for more than 5 min after an intravenous
bolus injection [302]. Most ultrasound contrast agents are eliminated
within a few minutes through the lungs. The blood clearance of func-
tionalized CNTs in mice is about 3 h post-injection [303]. This suggests
the possibility of eventually using CNTs in the long ultrasonography
investigations associated with therapy. CNTs can also contain therapeu-
tic agents [304,305]. A few studies have proposed a combination
of microbubble ultrasound contrast agents with a therapeutic
load or with targeting compounds [306,307]. Research focusing on
microbubbles as DDS and target-speciﬁc compounds is at an early
stage of development as compared to research on using CNTs as
target-speciﬁc DDS for image-guided therapy [289,308,309].
SWCNTs also exhibit high-resonance Raman scattering because of
their sharp electronic densities of state. This characteristic has been
exploited for in vitro and ex vivo imaging [310]. CNTs have also been
used as multicolor contrast agents for multiplexed Raman imaging
[311]. SWCNTs conjugated with targeting peptides may also be used
in photoacoustic imaging [312,313]. Photoacoustic imaging is currently
amajor focus of scientiﬁc research, but it has also begun to be applied in
the clinic [314].
Finally, CNTs and graphene are relatively safe in composition as
compared to other inorganic nanomaterials such as QDs, which usually
contain heavy metals, CNTs' safety and circulation dynamics have been
demonstrated for in vivo animal studies, and they may be more readily
translated than other inorganic nanoparticles [315,316].
11. Conclusion
Non-invasive, high-resolution in vivo imaging of tumors plays a key
role in the development of techniques for nano-pathophysiological im-
aging and theranostics in vivo. The incorporation of nano-DDSs bearing
MR contrast agents can enable visualization of a drug's distribution and
its therapeutic effects. The imaging of nano-DDS will provide informa-
tion for alternative options in caseswhere the delivered drug concentra-
tion or the therapeutic effect is found to be insufﬁcient. Even in the same
type of cells, diseases such as tumors have a heterogeneous microenvi-
ronment that changes depending on staging, treatment, and immune
response. Thus, nano-DDSs should be tailored to the speciﬁc diseasemi-
croenvironment. Fortunately, nano-DDSs form a wide range of mate-
rials, sizes, and functional properties. For example, nanomicelles are
suitable for delivering a wide range of markers and therapeutics agents.
Several therapeutic nanomicelles incorporating hydrophobic drugs are
under clinical trials. Moreover, in addition to FDA-approved PEGylated
liposomes, several types of biocompatible nano-materials, such as
nano-gels [317,318], are showing promise for clinical applications. In
conclusion, Nano-DDSs is a ﬂexible, growing technology that will be
broadly important for clinical diagnostics and therapy in the future.
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